Low-dose doxepin: In the treatment of insomnia

CNS Drugs

Volumn 24, Issue 8, 2010, Pages 713-720

  Weber, Juliane ^a   Siddiqui, M Asif A ^a   Wagstaff, Antona J ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Doxepin, therapeutic use; Insomnia; Sleep disorder therapies, therapeutic use; Tricyclic antidepressants, therapeutic use

Indexed keywords

DOXEPIN; HISTAMINE H1 RECEPTOR; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LOW DRUG DOSE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; REVIEW; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SLEEP WAKING CYCLE; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; ADULT; CLINICAL TRIAL (TOPIC); FEMALE; MALE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS AS TOPIC; DOXEPIN; FEMALE; HUMANS; MALE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 77954998734     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11200810-000000000-00000     Document Type: Review

References (27)

1. Diagnostic and statistical manual of mental disorders. Fourth edition, Text Revision. Washington, DC: American Psychiatric Association, 2000
2. Krystal AD. Treating the health, quality of life, and func-tional impairments in insomnia. J Clin Sleep Med 2007 Feb 15; 3 (1): 63-72
3. Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006 May; 12: S214-20
4. Becker PM. Pharmacologic and nonpharmacologic treat-ments of insomnia. Neurol Clin 2005 Nov; 23 (4): 1149-1163
5. Passarella S, Duong MT. Diagnosis and treatment of in-somnia. Am J Health Syst Pharm 2008; 65 (10): 927-934
6. Tariq SH, Pulisetty S. Pharmacotherapy for insomnia. Clin Geriatr Med 2008; 24 (1): 93-105
7. Somaxon Pharmaceuticals Inc. Somaxon presents pharmaco-logical data on doxepin at the 21st European College of Neuropsychopharmacology Congress [media release]. 2008 Sep 3
8. Mansbach R. In vitro pharmacological profile of doxepin, a sleep-promoting histamine H1 antagonist [abstract no. P.2.d.023]. Eur Neuropsychopharmacol 2008; 18 Suppl. 4: S357.
9. Plus poster presented at the 21st Congress of the European College of Neuropsychopharmacology; 2008 Aug 30-Sep 3; Barcelona
10. Somaxon Pharmaceuticals Inc. Silenor® (doxepin) tablets for oral administration: US prescribing information [online]. Available from URL: http://www.silenor.com/pdf/Full-Package-Insert.Silenor.pdf [Accessed 2010 Jun 8]
11. Stahl SM. Selective histamine H1 antagonism: novel hyp-notic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008 Dec; 13 (12): 1027-1038
12. Singh H, Becker PM. Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs 2007 Aug; 16 (8): 1295-1305
13. Rodenbeck A, Cohrs S, Jordan W, et al. The sleep-improv-ing effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia: a placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psycho-pharmacology (Berl) 2003 Dec; 170 (4): 423-428
14. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996 Sep; 29 (5): 187-192
15. Lankford A, Hull S, Scharf MB, et al. Efficacy and safety of doxepin 3 and 6 mg in adults with primary insomnia [abstractno. NR593 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 253-254
16. Lankford A, Hull S, Scharf M, et al. Efficacy and safety of doxepin 3 and 6 mg in adults with primary insomnia [abstract no. 0750]. Sleep 2007; 30 Suppl.: A256. Plus oral presentation from the 21st Annual Meeting of the Associated Professional Sleep Societies; 2007 Jun 9-14; Minneapolis (MN)
17. Krystal A, Lankford A, Jochelson P, et al. Efficacy of dox-epin 3 and 6mg on early morning awakenings in adults with primary insomnia [abstract no. NR6-084 plus poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
18. Jochelson P, Gotfried M, Hull S, et al. Efficacy and safety of doxepin 1 and 3mg in a 3-month trial of elderly adults with chronic primary insomnia [abstract no. NR6-090]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC, 316
19. Roth T, Gotfried M, Hull S, et al. Long-term efficacy and safety of doxepin 1 and 3mg in elderly subjects with chronic primary insomnia [abstract plus poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
20. Roth T, Durrence H, Gotfried M, et al. Efficacy and safety of doxepin 1 and 3mg in a 3-month trial of elderly adults with chronic primary insomnia [abstract no. 0701]. Sleep 2008; 31 Suppl.: A230. Plus oral presentation from the 22nd Annual Meeting of the Associated Professional Sleep Societies; 2008 Jun 7-12; Baltimore (MD)
21. Segal S, Lankford A, Borders J, et al. Efficacy and safety of doxepin 6 mg in a 4-week outpatient trial of elderly adults with primary insomnia [abstract no. NR6-091]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC, 316-317
22. World Intellectual Property Organization. (WO/2008/011150) Methods of improving the pharmacokinetics of doxepin [online]. Available from URL: http://www.wipo.int/pctdb/en/wo.jsp?WO=2008011150&IA=US2007016464& DISPLAY=DESC [Accessed 2008 Sep 3]
23. Virtanen R, Scheinin M, Iisalo E. Single dose pharmaco-kinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol 1980 Nov; 47 (5371-76)
24. Lankford A, Krystal A, Durrence H, et al. Doxepin 3 and 6mg in a 35-day trial of adults with primary insomnia: effects following discontinuation [abstract no. 0783]. Sleep 2008; 31 Suppl.: A256-7. Plus poster presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies; 2008 Jun 7-12; Baltimore (MD)
25. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia. Sleep 2007 Nov 1; 30 (11): 1555-1561
26. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1mg, 3mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008 Oct; 69 (10): 1557-1564
27. Schwartz H, Hull S, Seiden D, et al. Efficacy and safety of doxepin 6mg in a model of transient insomnia [abstract no. NR594 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 254